Contineum (CTNM) announced authorization of its investigational new drug, or IND, application from FDA for PIPE-791 for the treatment of chronic pain associated with two separate indications, ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
“We have done screens of over 2 million compounds and gotten anywhere from zero to tens of promising leads from screen hits, so if you screen any less chemical space, there is lower chance of ...